Business Context and Reporting Period
The provided filing is a Form 10-K for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. It covers the fiscal year ended December 31, 2013, and was filed March 31, 2014. Zeta was a Delaware development-stage, blank-check and shell company formed to pursue a business combination. It had identified no target, entered no definitive agreement, and generated no operating revenue since inception.
The company had no employees apart from its officers, used management-provided office space at no cost, and its common stock was not publicly traded. Management expected to devote limited time to the company until a business combination was identified.
Key Financial Metrics
| Metric | 2013 | 2012 |
|---|---|---|
| Total assets | $8,783 | $8,107 |
| Cash and cash equivalents | $6,283 | $4,607 |
| Total liabilities | $133,025 | $103,648 |
| Notes payable to stockholders | $110,000 | $85,000 |
| Stockholders’ deficit | $(124,242) | $(95,541) |
| Revenue | $0 | $0 |
| Net loss | $(28,701) | $(27,365) |
| Basic and diluted loss per share | $(0.01) | $(0.01) |
| Net cash used in operating activities | $(23,324) | $(24,518) |
| Net cash provided by financing activities | $25,000 | $25,000 |
Operating expenses were $22,824 in 2013 versus $22,391 in 2012. Interest expense increased to $5,877 from $4,974. The company had no investing cash flows. Stockholder loans received during 2013 totaled $25,000; the unsecured notes bear interest at 6% and are due on demand. Accrued and unpaid interest was $17,175 at year-end.
No meaningful revenue or operating margin exists because the company had no active operations. The company reported cumulative net losses of $174,242 from inception on November 16, 2007 through December 31, 2013.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $1,336, or approximately 4.9%, from $27,365 to $28,701.
- Operating cash use improved by $1,194, from $24,518 to $23,324.
- Cash increased by $1,676 to $6,283, primarily because $25,000 of stockholder financing exceeded operating cash needs.
- Total liabilities increased by $29,377, including a $25,000 increase in stockholder notes payable and a $5,877 increase in accrued interest.
- Stockholders’ deficit increased by $28,701 to $124,242, reflecting the 2013 net loss.
- The company continued to have no revenue, no identified acquisition target, and no business combination agreement.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management’s plan was to continue searching for a suitable acquisition candidate and to fund reporting, investigation, and transaction costs through existing cash, deferred service-provider fees, additional stockholder or management loans, and potential equity financing in a reverse merger. The filing provides no forecast for revenue, earnings, cash flow, or timing of a transaction.
- Going concern: Management stated that continuation depends on future financing, profitable operations, and/or completing a suitable business combination. The company cannot assure that it can meet cash requirements for the following twelve months.
- Funding dependence: The company had only $6,283 of cash at year-end and depended on related parties for continued funding. Stockholder notes were unsecured and payable on demand.
- Business-combination risk: No target had been identified, and any future target could be financially unstable, early-stage, or operating in a high-risk industry.
- Dilution and control: A transaction would likely issue substantial equity to a target’s owners, potentially leaving existing stockholders with 20% or less of the surviving entity and potentially changing the board and management without a stockholder vote.
- Limited diversification: Management expected it would likely complete only one business combination, increasing concentration risk.
- Tax assets: The company reported an approximately $17,200 federal and state net operating loss carryforward, but recognized no deferred tax asset because a full valuation allowance was recorded.
- Unusual corporate status: The company was a blank-check and shell company, an emerging growth company, and a smaller reporting company. Its auditor issued an unqualified opinion but did not provide an internal-control attestation.
- Legal and off-balance-sheet matters: No material pending legal proceedings or material off-balance-sheet arrangements were reported.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing names Zeta Acquisition Corp. II, while the request identifies Whitehawk Therapeutics, Inc.
- Verify whether any business combination, reverse merger, name change, or other subsequent event occurred after December 31, 2013.
- Review the terms, holders, maturity, and repayment status of the $110,000 in stockholder notes and $17,175 of accrued interest.
- Assess the company’s ability to continue as a going concern given $6,283 of cash, $133,025 of liabilities, no revenue, and reliance on related-party funding.
- Verify ownership and dilution implications: officers and directors collectively held 80% of the 5,000,000 outstanding common shares.
- Review the audited financial statements and subsequent filings for any identified acquisition target, financing, change in control, or securities issuance.